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Abstract  The  aim  of  our  study  was  to  describe  the  distribution  of  Visceral  Leish-
maniasis  (VL)  in  Italy,  focusing  on  HIV-infected  patients,  to  estimate  the  burden
of  the  disease  and  the  public  health  actions  that  should  be  undertaken.  A  review
of  ofﬁcial  notiﬁcations  and  hospitalization  data  has  been  performed.  From  2006  to
2008,  a  total  of  289  cases  of  VL  were  notiﬁed;  the  overall  notiﬁcation  rate  was
1.63/1,000,000  (95%  CI  1.45—1.83).  In  total,  1192  VL-associated  hospitalizations
were  detected,  with  a  hospitalization  rate  of  6.71/1,000,000  (95%  CI  6.34—7.10).
For  the  age  group  ‘‘≤24  years’’,  a  statistically  signiﬁcant  increase  was  detected
(p  <  0.05).  A  total  of  68.9%  (n  =  821)  of  hospitalizations  were  detected  in  HIV-positive
patients.  The  geographic  distribution  of  rates  revealed  a  signiﬁcant  increase  in  the
north-eastern  area  of  the  country.  Our  study  conﬁrms  that  the  epidemiological  pat-
tern  of  VL  is  changing  and  that,  in  Italy,  control  measures  and  preventive  strategies
should  be  based  on  not  only  the  ofﬁcial  notiﬁcation  system  but  also  hospital  data.
This  would  lead  to  the  identiﬁcation  of  areas  of  parasite  spread  and  to  the  creation
of  awareness  campaigns  geared  toward  general  practitioners  in  the  affected  areas.
Easy  case  detection  would  allow  for  timely  public  health  actions  and  strategies  for
the  implementation  of  more  effective  interventions  for  reservoir  control.
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eishmaniasis  is  a major  vector-borne  infection
aused by  more  than  20  leishmanial  protozoa  and
s transmitted  to  humans  by  approximately  30
ifferent  species  of  Phlebotomine  sandﬂies  [1].
eishmaniasis  is  endemic  in  the  Mediterranean
asin and  in  large  areas  of  the  tropics  and  subtrop-
cs [2].  The  host  inﬂammatory  immune  response
 Sciences. Published by Elsevier Ltd. All rights reserved.



























regulates  the  expression  and  the  outcome  of  the
disease  [3].  Symptomatic  disease  is subacute  or
chronic and  diverse  in  presentation  and  outcome.
Without treatment,  visceral  leishmaniasis  is  almost
universally  fatal  [4].
The human  disease  is  present  in  two  different
epidemiological  and  clinical  forms:  visceral  leish-
maniasis  (VL)  and  cutaneous  leishmaniasis  (CL).
Dogs are  considered  to  be  the  major  host  for  these
parasites  and  the  main  reservoir  for  human  visceral
infection  [5].  VL  is  a  typical  rural  and  periurban  dis-
ease and  is  present  in  patchy  spots  along  areas  of
the Tyrrhenian  Coast,  the  low  Adriatic  Coast  and  in
the Islands,  according  to  the  biological  characteris-
tics of  the  vectors.  Cases  of  VL  have  been  reported
in many  regions  of  the  center-south,  but  the  most
affected  areas  are  in  Campania  and  Sicily  [2,5]. The
mean increase  in  atmospheric  temperature  could
possibly  favor  the  diffusion  of  VL  and  its  vectors  into
regions of  northern  Italy  that,  until  a  few  years  ago,
were untouched,  with  only  sporadic  cases  of  canine
leishmaniasis  reported.  The  increase  in  tempera-
ture could  also  increase  the  incidence  of  VL  in  the
regions  where  it  is  already  endemic  [6].  Moreover,
co-infection of  Leishmania  and  human  immunode-
ﬁciency virus  (HIV)  has  emerged  as  a  serious  health
concern  [7—11], and  VL  promotes  the  clinical  pro-
gression  of  HIV  disease  [12].
In Italy,  VL  is  a  notiﬁable  disease;  however,  infec-
tion reporting  is  not  rigorous  in  all  regions,  meaning
that VL  could  be  underreported  [13].
The aim  of  our  study  was  to  describe  the  distri-
bution of  VL  in  Italy,  with  a  focus  on  HIV-infected
patients, to  assess  the  burden  of  the  disease  and  the
public health  actions  that  should  be  undertaken.
Materials and methods
In Italy,  VL  is  a  notiﬁable  disease;  the  number  of
VL ofﬁcial  notiﬁcations  for  the  period  from  2006
to 2008  was  retrieved  from  the  Ministry  of  Health
website. In  Italy,  the  national  surveillance  system
for communicable  diseases  was  revised  in  1990.
Notiﬁable  diseases  were  grouped  into  ﬁve  cate-
gories, deﬁned  according  to  the  urgency  with  which
they must  be  reported  and  the  type  of infor-
mation to  be  collected.  Italy  is  divided  into  20
geographic  regions,  each  of  which  has  a regional
health authority  responsible  for  public  health  activ-
ities. Speciﬁcally,  within  each  region,  there  are  a
number of  health  facilities  known  as  local  health
units that,  through  a  department  known  as  the  pub-
lic health  service,  are  responsible  for  local  public




oig.  1  Distribution  of  Italian  regions  by  ISTAT  geograph-
cal  areas.
ll  conﬁrmed  and  suspected  cases  of  communica-
le diseases  to  the  public  health  service  of  the
ocal health  unit.  The  local  health  unit  then  groups
he cases  and  sends  them  to  the  Regional  Health
uthority, which  forwards  the  data  to  the  national
evel,  namely  the  Ministry  of  Health,  the  National
nstitute of  Health  (ISS)  and  the  National  Institute
f Statistics  (ISTAT)  [14].
The resident  population  was  estimated  using
ata from  the  Italian  National  Institute  of  Statis-
ics (http://demo.istat.it/); population  data  were
btained according  to  sex,  age  groups  (<15;
5—24 years;  25—64  years;  ≥65  years)  and  geo-
raphical region  The  Italian  regions  are  follows:
orth—West (Valle  d’Aosta,  Piemonte,  Liguria,
ombardia); North—East  (Trentino  Alto  Adige,
eneto, Friuli—Venezia—Giulia,  Emilia—Romagna);
enter (Toscana,  Marche,  Umbria,  Lazio);  South
Campania,  Abruzzi,  Molise,  Basilicata,  Puglia,
alabria);  and  the  Islands  (Sicilia,  Sardegna).  The
istribution  of  Italian  regions  by  geographical  areas
s shown  in  Fig.  1. Data  on  hospitalizations  came
rom the  Italian  Ministry  of  Health;  the  hospital
ischarge record  is  a synthesis  of  the  patient’s  med-
cal record  and  is  mandatory  for  both  inpatients
nd outpatients  and  contains,  for  each  hospital  dis-
harge in  Italy,  the  social  and  demographic  data  of
he patient  (i.e.  age,  gender,  place  of  birth,  place
f residence)  and  the  clinical  data  (‘‘principal’’
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Table  1  Number  of  Visceral  Leishmaniasis  (VL)  notiﬁcations  and  temporal  trend  of  VL  notiﬁcations  incidence  rates
(rate  between  VL  notiﬁcations  and  population  ×  1,000,000),  for  age  groups,  from  2006  to  2008,  in  Italy.
2006  2007  2008  pa
n◦ Rate  [95%  CI]  n◦ Rate  [95%  CI]  n◦ Rate  [95%  CI]
≤24  years 34  2.37  23  1.60  25  1.73  N.S.
[1.67—3.27] [1.04—2.36] [1.15—2.51]
25—64  years 60  1.83  64  1.94  35  1.05  <0.05  ↓
[1.41—2.34]  [1.51—2.46]  [0.75—1.45]
≥65  years 19  1.64  17  1.44  12  1.00  N.S.
[1.02—2.51]  [0.87—2.26]  [0.55—1.70]
Global  113  1.92  104  1.76  72  1.21  <0.05


































































9a Cochrane—Armitage test for linear trend.
iagnosis  and  up  to  ﬁve  other  diagnoses,  proce-
ures and  outcomes).  Diagnoses  and  procedures
re coded  using  the  International  Classiﬁcation  of
iseases, 9th  revision,  Clinical  Modiﬁcation  (ICD-
 CM).  Data  from  all  over  Italy  are  collected  in
he National  Hospital  Discharge  Database,  available
rom  the  Ministry  of  Health.  Hospital  discharge  data
ere examined  for  the  3-year  period  2006—2008.
 VL-associated  hospitalization  event  was  deﬁned
s a  hospitalization  for  which  the  ICD-9-CM  code
‘085:  Visceral  Leishmaniasis’’  was  listed  among  the
ischarge diagnosis  (one  principal  and  up  to  ﬁve
econdary  diagnoses).  Each  hospitalized  patient  is
dentiﬁed by  a  single  (anonymous)  ID  code  that
as allowed  us  to  consider  only  the  ﬁrst  VL-
ssociated hospitalization  event;  thus,  we  have
he possibility  to  exclude  readmissions  for  relapses
r maintenance  of  therapy  in  the  same  individ-
al. VL-associated  hospitalizations  were  analyzed
ccording  to  the  year  of  discharge,  patient’s  sex,
ge groups  (≤24  years;  25—64  years;  ≥65  years),
eographical region  of  residence,  co-infection  with
IV and  nationality.  Hospitalizations  relating  to  HIV-
nfected patients  were  identiﬁed  by  searching  for
he ICD-9-CM  code  ‘‘042:  Human  immunodeﬁciency
irus [HIV]  disease’’  among  the  discharge  diagnosis
one  principal  and  up  to  ﬁve  secondary  diagnoses).
dditionally, in  this  case,  all  re-hospitalizations
ere excluded  according  to  the  ID  code  available
or each  patient.
All data  used  in  this  analysis  were  released  in
n anonymous  form;  therefore,  the  approval  of  an
thics Committee  was  not  required.
The rates  of  VL  notiﬁcations  and  hospitaliza-
ions were  calculated  by  dividing  the  number  of
otiﬁcations  by  the  resident  population  in  each
egion.  All  rates  were  expressed  per  1,000,000  peo-
le in  the  resident  population.  Conﬁdence  intervals
ere calculated  using  the  Poisson  approximation.
 Cochran—Armitage  test  for  trend  [15,16]  was
t
i
ised  to  assess  the  signiﬁcance  levels  of  variation
f notiﬁcation  and  of  hospitalization  rates  over  the
ears in  different  geographical  areas  of  the  country.
nder-reporting  was  estimated,  on  a  regional  basis,
y calculating  the  proportion  of  notiﬁed  cases  over
he number  of  hospitalizations.
Statistical  analysis  was  performed  using  Stata
oftware package  9.0.  [17]. The  level  of  signiﬁcance
as set  at  0.05.
esults
otiﬁcations
uring  2006—2008,  a total  of  289  cases  of  VL  were
otiﬁed  in  Italy;  the  overall  notiﬁcation  rate  was
.63/1,000,000  (95%  CI  1.45—1.83).  The  notiﬁca-
ion rate  was  higher  in  males  (2.24/1,000,000;  95%
I 1.93—2.58)  than  in  females  (1.05/1,000,000;  95%
I 0.85—1.28).
The  temporal  trend  of  VL  notiﬁcations  rates  by
ge groups  was  analyzed  (Table  1):  globally,  in  Italy,
 statistically  signiﬁcant  reduction  in  notiﬁcation
ates was  detected  (p  < 0.05).  In  particular,  the
ecrease  was  statistically  signiﬁcant  for  the  25—64-
ear age  group  (p  < 0.05).
ospitalizations
uring  the  same  period,  1192  VL-associated  hospi-
alizations  were  registered;  the  global  hospitaliza-
ion rate  was  6.71/1,000,000  (95%  CI  6.34—7.10).
he rate  was  higher  in  males  (9.33/1,000,000;  95%
I 8.70—10.01)  than  in  females  (4.23/1,000,000;
5% CI  3.82—4.68).
The temporal  trend  of  VL-associated  hospitaliza-
ion rates  during  the  years  2006—2008  by  age  groups
s shown  in  Table  2.  Globally,  in  Italy,  an  increase
n the  VL-associated  hospitalization  was  observed,
468  G.H.  Abdalmaula  et  al.
Table  2  Number  of  VL  hospitalizations  and  temporal  trend  of  VL  hospitalizations  incidence  rates  (rate  between
VL-associated  hospitalizations  and  population  ×  1,000,000),  for  age  groups,  from  2006  to  2008,  in  Italy.
2006  2007  2008  pa
n◦ Rate  [95%  CI]  n◦ Rate  [95%  CI]  n◦ Rate  [95%  CI]
≤24  years 28 1.95  68  4.73  194  13.43  <0.05  ↑
[1.32—2.78] [4.69—4.77] [11.64—15.42]
25—64  years 314 9.57  115  3.49  221  6.65  <0.05  ↓
[8.56—10.68]  [2.89—4.17]  [5.82—7.57]
>65  years 80 6.90  118  10.01  54  3.74  <0.05  ↓
[5.51—8.54]  [8.32—11.94]  [2.78—4.99]
Global  422  7.18  301  5.09  469  7.87  N.S.
[6.52—7.89]  [4.5
although  the  trend  was  not  statistically  signiﬁcant
(p > 0.05).  There  were  signiﬁcant  decreases  in  VL-
associated  hospitalization  for  the  25—64-year  and
≥65-year  age  groups  (p  <  0.05),  while  for  the  ≤24-
year age  group,  a  statistically  signiﬁcant  increase
was detected  (p  <  0.05).
Among the  1,192  VL-associated  hospitalizations,
68.9% (n  =  821)  involved  HIV-positive  patients,  and
70.1% (n  =  576)  of  them  occurred  in  male  patients
(p < 0.05).
Fig.  2  reports  the  distribution  of  the  percentage
of notiﬁed  VL  cases  with  respect  to  the  registered
hospitalizations,  underlining  a  quite  different  dis-
tribution of  trends,  with  endemic  regions  (from
certain  Southern  and  Tyrrhenian  areas)  experienc-
ing higher  notiﬁcation  rates,  whereas  Central  (i.e.,
Toscana) and  Northern  (i.e.,  Emilia—Romagna)
regions  experienced  higher  levels  of  underreport-
ing.
Fig.  2  Under-reporting  estimates  (proportion  of  VL  noti-
ﬁed  cases  over  the  number  of  VL  hospitalizations)  in





































In  Table  3,  the  rates  of  VL-associated  hospitaliza-
ions for  HIV-positive,  HIV-negative  and  all  patients
re reported  according  to  sex,  age  group  and  geo-
raphical  region.  We  observed  that  VL-associated
ospitalizations  occurred  more  frequently  in  men
han in  women  for  both  categories  of  patients.  The
nalysis of  VL-associated  hospitalization  rates  by
ge groups  highlights  that  in  HIV-positive  patients,
ncreases  in  patients  ≤24  years  and  ≥65  years
ere identiﬁed,  while  a reduction  was  noted  in  the
5—64-year  age  group.  An  increase  in  VL-associated
ospitalizations  for  the  ≤24-year  age  group  was
oted in  HIV-negative  patients;  no  changes  were
etected  over  the  three-year  period  for  the  25—64-
ear age  group,  while  a  reduction  was  detected
or patients  ≥65  years.  When  considering  the  geo-
raphical  region  of  residence,  increasing  trends  of
L-associated  hospitalizations  rates  were  detected
p <  0.05)  for  the  North-eastern  and  North-western
egions, while  the  rates  were  stable  in  the  Center
nd South;  moreover,  a signiﬁcant  reduction  was
bserved  in  the  Islands  (p  < 0.05).  The  same  pat-
ern was  observed  when  both  the  HIV-positive  and
IV-negative  patients  were  considered  separately.
mong the  821  VL-associated  hospitalizations  for
IV-positive  patients  and  the  371  hospitalizations
or HIV-negative  patients,  90.5%  and  97.6%  were
talians,  respectively.
iscussion
ur  study  highlights  a non-homogeneous  trend  of
L-associated  hospitalizations  and  notiﬁcations  in
taly that  is  consistent  both  with  rates  detected
n a  previous  Italian  study  [18]  and  with  glob-
lly reported  trends.  In  fact,  while  the  infection
s declining  according  to  the  ofﬁcial  surveillance
ystem based  on  notiﬁcations,  the  number  of













Table  3  VL  notiﬁcations  by  HIV  status,  according  to  sex,  age  groups,  and  region,  Italy  2006—2008.
LV-associated hospitalizations, rate/1,000,000 population [95% CI] by HIV status, region and sex
HIV-positive HIV-negative All
Variable 2006 2007 2008 pa 2006 2007 2008 pa 2006 2007 2008 pa
Sex
Male 7.08 (202) 5.4(155) 8.5(246) <0.05 3.01(86) 1.92(55) 2.11(61) <0.05 10.09(288) 7.32(210) 10.61(307) NS
[6.15—8.11] [4.60—6.30] [7.48—9.61] [2.43—3.70] [1.46—2.47] 1.63—2.69 [8.96—11.33] [6.35—8.37] [9.45—11.85]
Female  1.95(59) 1.51(46) 3.68(113) <0.05 2.48(75) 1.48(45) 1.6(49) <0.05 4.43(134) 2.99(91) 5.28(162) NS
[1.50—2.50]  [1.12—2.00] [3.05—4.41] [1.97—3.09] [1.09—1.96] 1.20—2.09 [3.71—5.25] [2.4—3.67] [4.5—6.16]
Age  group, years
≤24 years 0 0.70 (10) 9.90(143) <0.05 1.95(28) 4.03(58) 3.53(51) <0.05 1.95(28) 4.73(68) 13.43(194) <0.05 ↑
[0.00—0.21]  [0.36—1.23] [8.37—11.62] [1.32—2.78] [3.09—5.18] 2.66—4.60 [1.32—2.78] [4.69—4.77] [11.64—15.42]
25—64  years 7.65(251) 2.21(73) 4.88(162) <0.05 1.92(63) 1.27(42) 1.77(59) NS 9.57(314) 3.49(115) 6.65(221) <0.05 ↓
[6.75—8.64]  [1.75—2.77] [4.17—5.67] [1.49—2.44] [0.93—1.70] 1.36—2.27 [8.56—10.68] [2.89—4.17] [5.82—7.57]
≥65  years 0.86(10) 10.01(118) 4.52(54) <0.05 6.04(70) 0 0  <0.05 6.90(80) 10.01(118) 4.52(54) <0.05 ↑
[0.44—1.53] [8.32—11.94] [3.43—5.85] [4.75—7.58] [0.00—0.25] 0.00—0.03 [5.51—8.54] [8.32—11.94] [3.43—5.85]
Regionb
Northwest 4.15(47) 4.36(50) 8.86(99) <0.05 1.77(20) 2.65(29) 2.15(24) NS 6.05(67) 7.02(79) 11.01(123) <0.05 ↑
[3.63—4.69]  [3.84—4.92] [8.11—9.64] [1.44—2.14] [2.24—3.09] [1.79—2.55] [5.43—6.71] [6.35—7.72] [10.17—11.87]
Northeast  0.69(11) 0.49(8) 5.65(87) <0.05 0.25(4) 0.13(2) 0.77(12) <0.05 0.97(15) 0.62(10) 6.42(99) <0.05 ↑
[0.49—0.93]  [0.32—0.70] [5.05—6.28] [0.13—0.40] [0.05—0.41] [0.55—1.01] [0.72—1.25] [0.43—0.85] [5.78— 7.09]
Center  6.42(73) 4.49(53) 5.68(65) NS 2.26(26) 1.80(20) 1.40(16) NS 8.77(99) 6.29(73) 7.07(81) NS
[5.77—7.08] [3.96—5.06] [5.08—6.31] [1.89—2.68] [1.47—2.17] [1.11—1.73] [8.02—9.56] [5.66—7.09] [6.40— 7.78]
South  5.63(76) 4.20(53) 3.47(50) <0.05 6.45(86) 2.19(33) 2.51(38) <0.05 11.50(162) 6.39(86) 5.98(88) <0.05 ↓
[5.03—6.27]  [3.69—4.75] [3.00—3.97] [5.81—7.13] [1.81—2.59] [2.11—2.94] [10.64—12.40] [5.75—7.05] [5.37—6.63]
Islands  8.39(54) 5.95(37) 8.38(58) NS 3.62(25) 2.32(16) 2.91(20) NS 11.85(79) 8.27(53) 11.30(78) NS
[7.66—9.16]  [5.34— 6.60] [7.65—9.15] [3.14—4.13] [1.94—2.73] [2.49—3.37] [10.97—12.70] [7.55—9.03] [10.45—12.18]
Total Italy  4.44(261) 3.40(201) 6.02(359) <0.05 2.74(161) 1.69(100) 1.84(110) <0.05 7.18(422) 5.09(301) 7.86(469) NS
[3.93—5.01]  [2.95—3.89] [5.42—6.67] [2.34—3.19] [1.38—2.05] [1.52—2.21] [6.52—7.89] [4.54—5.69] [7.18—8.60]
a Cochrane—Armitage test for linear trend; NS:Not Signiﬁcant.

















































it is  interesting  to  note  that  the  increase  in
VL-associated hospitalizations  is  statistically  sig-
niﬁcant just  in  those  geographical  areas  in  the
north of  the  peninsula,  where  the  disease  was
not endemic  until  recently  [19,20].  This  result  is
in line  with  the  increasing  seroprevalence  that
was estimated  in  the  canine  population  of  north-
ern Italy  in  a  recent  study  by  Franco  et  al.  [21].
Moreover,  the  differences  detected  at  the  regional
level could  not  be  ascribed  to  local  differences  in
health care  systems  because  the  Italian  National
Healthcare Service  is characterized  by  universal
coverage, which  entitles  all  citizens,  regardless
of their  social  status,  to  equal  access  to  essen-
tial health  care  services.  Essential  health  services
are provided  free  of  charge  or  at  very  low  cost
(namely ‘‘ticket’’)  and  include  general  medical
and pediatric  services,  essential  drugs  and  those
for chronic  diseases,  treatments  administered  dur-
ing hospitalization,  rehabilitation  and  long-term
post-acute inpatient  care,  instrument  and  labo-
ratory  diagnostics  and  other  specialized  services
for early  diagnosis  and  prevention.  Finally,  the
National  Healthcare  Service  guarantees  that  the
system is  subject  to  popular  democratic  control  at
the national,  regional  and  local  levels  (participa-
tion).
Moreover, by  observing  the  VL-associated  hospi-
talization  temporal  trends  stratiﬁed  for  age  groups,
we can  highlight  an  increase  in  the  ≤24-year  age
group and  reductions  in  the  other  groups.  This
trend conﬁrms  the  typical  epidemiological  pat-
tern of  VL  in  the  Mediterranean  basin,  where  it
predominantly  affects  children  [2].  The  children’s
nationality  information  conﬁrms  that  they  were  all
Italian; thus,  all  of  the  hospitalized  VL  cases  were
likely locally  acquired,  although  it  is  not  possible
to exclude  that  the  disease  was  acquired  during
travel abroad.  It  is  not  easy  to  guess  the  reasons
for this  sharp  increase  without  a  direct  analysis  of
each case;  however,  we  might  hypothesize  that  the
increase could  be  linked  to  the  intensiﬁcation  of
travel in  endemic  areas  [22]  and  migration  ﬂows
from  endemic  countries.  Moreover,  some  speciﬁc
scientiﬁc  studies  have  been  conducted  in  Northern
areas of  Italy  whose  objectives  were  to  detect  VL
in children  [23,24].
When  analyzing  the  temporal  trends  by  age
groups according  to  the  HIV  status  of  the  hospital-
ized patients,  among  the  HIV-positive  patients,  we
observed a  statistically  signiﬁcant  increase  for  the
VL-associated  hospitalization  rate  in  the  ≥65-year
age group.  This  ﬁnding  is  consistent  with  ﬁndings
from a  Portuguese  study  that  reported  that  VL  was
traditionally  a  pediatric  disease,  but  that  in  the
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as  decreased,  with  an  increase  in  the  number
f infections  in  adults,  which  are  often  associated
ith HIV/AIDS  [25].  Moreover,  our  results  highlight
hat  69.8%  of  VL-associated  hospitalizations  are
IV-positive  patients,  and  among  these,  70.1%  are
ales; these  observations  are  in  accordance  with
 study  conducted  in  2005  in  Spain,  where  83%  of
IV-infected  patients  with  VL  were  male  [26].
Early diagnosis  and  treatment  of  VL  infection
s challenging  because  physicians  are  not  expe-
ienced  with  the  disease.  The  variety  of  clinical
resentations, the  long  incubation  period  [27],  and
atients’ unusual  travel  histories  prejudice  timely
ublic  health  actions  and  effective  strategies  for
he control  of  VL.  It is  well  known  that  climatic
actors can  inﬂuence  the  appearance  or  reappear-
nce of  infectious  diseases  in  a particular  area  when
here are  other  biological,  ecological  and  socioeco-
omic factors  that  are  favorable  for  the  event,  with
oncomitant  increases  in  incidence  [28].
Underreporting  is  common  in  VL  [29]; this  is
artly due  to  asymptomatic  infections  and  caveats
n available  data  sources  [30].  In  a study  conducted
n 1975,  it was  estimated  that  for  1  clinical  case
f VL,  there  may  be  30—100  subclinical  infections
31,32].  This  phenomenon  is  particularly  worry-
ng considering  that  the  patients  are  hospitalized
or VL;  the  physicians  working  in  the  hospitals
ave the  duty  to  notify  to  the  Hygiene  and  Pub-
ic Health  Services  of  all  newly  infected  patients.
n Italy,  VL  notiﬁcation  is  compulsory  within  48  h  of
iagnosis, according  to  a  Ministerial  decree  of  15
ecember 1990  [33].  Moreover,  the  apparent  dis-
onnect  between  hospitalizations  and  notiﬁcations
mphasizes the  fact  that  hospital  physicians  are  not
ware of  the  importance  of  infectious  disease  noti-
cation  for  public  health  policy.
Moreover, this  underestimate  could  have  severe
onsequences, especially  when  blood  donors  are
nfected  [34,35]. The  role  of  underestimation  is
ighlighted  in  Fig.  2, emphasizing  that  underreport-
ng in  non-endemic  areas  could  be  an  indication  of
he need  for  speciﬁc  education  of  healthcare  pro-
essionals  on  the  diagnosis  and  notiﬁcation  of  VL  to
mprove preventive  strategies.
This study  has  some  limitations:  leishmaniasis  is
ransmitted  during  the  summertime,  so  knowledge
f the  travel  history  for  each  individual  patient  is
ssential. The  accurate  identiﬁcation  of sites  of
nfection  is  difﬁcult  and  cannot  be  derived  from
n anonymous  database  analysis.  Because  the  Ital-
an VL  notiﬁcation  system  does  not  include  clinical
uidelines  about  its  diagnosis,  the  identiﬁcation  of
ach VL  case  is  based  on  physicians’  expertise  and
he availability  of  laboratory  facilities  with  trained
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 detailed  analysis  of  the  epidemiology  of  VL  in
hildren  <1  year  of  age  because  the  notiﬁcation
ystem reports  data  grouped  for  all  children  under
5. Moreover,  accurate  entomological  and  canine
nfection  information  is  very  important  for  map-
ing risk  areas.  The  estimation  of  disease  burden
ould be  very  important  for  policy  makers  and  fund-
ng organizations  to  establish  priorities  for  research
n the  prevention,  diagnosis  and  treatment  of  this
eglected  infectious  disease.  In fact,  to  enhance
he efﬁcacy  of  control  strategies,  interdisciplinary
ollaborations  that  are  focused  on  reservoir  con-
rol (e.g.,  vaccines  for  canine  leishmaniasis  and
eltamethrine-treated  collars)  and  vector  control
re of  paramount  importance.
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